Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 10024 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 13391 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 13522 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 13846 | Peak area normalized | male | pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 14378 | Peak area normalized | female | normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 19866 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 21132 | Peak area normalized | male | pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 21209 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 22085 | Peak area normalized | male | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 25953 | Peak area normalized | female | normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 30769 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 36463 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 37231 | Peak area normalized | male | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | DEOXYADENOSINE (M+CL)- | 45976 | Peak area normalized | female | diabetic | no neuropathy |